Clinical trial · Observational
Quality of Life of Non-transplant Candidate Multiple Myeloma Patients Treated With Early Bortezomib
A Prospective, Open-label, Multicenter Observational Study to Evaluate the QoL of Non-transplant Candidate Multiple Myeloma Patients Treated With Early Bortezomib
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study will observe the degree of the quality of life in non-transplant candidate patients with multiple myeloma before and after bortezomib administration by using EORTC-QLQ C30 (European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core30) and EQ-5D (EuroQol-5 Dimensions). Both tools are validated research instruments used to measure the quality of life in cancer patients and consequently will provide fundamental data regarding the quality of life in patients with multiple myeloma by analyzing factors that affect the quality of life.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Multiple Myeloma | Multiple Myeloma | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| No intervention | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Bortezomib
- interventionNames
- Drug: No intervention
Primary outcomes (1)
- measure
- The change in the quality of life as measured by EORTC QLQ-C30 and EQ-5D before and after the administration of bortezomib
- timeFrame
- On day 1 at the first cycle, 12 weeks, 24 weeks
Secondary outcomes (5)
- measure
- Relationship between the primary outcome and the complete remission (CR) rate
- timeFrame
- 12 weeks and 24 weeks
- measure
- Relationship between the primary outcome and overall response
- timeFrame
- 12 weeks and 24 weeks
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 20 Years
Show eligibility criteria text
Inclusion Criteria: * Symptomatic multiple myeloma patient * ECOG score less than 3 * Patient is not a candidate for stem cell transplantation * Previous treatment duration is less than 6 months * Previous treatment response is less than partial response (PR) * Willing and able to complete the questionnaire * Patients (or their legally acceptable representatives) must have signed an informed consent document indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study Exclusion Criteria: * Known hypersensitivity to bortezomib * Acute severe infection requiring antibiotics therapy * Pre-existing peripheral neuropathy greater than or equal to grade 2 * Uncontrolled or severe cardiovascular disease * Pregnancy or breastfeeding
References
Publications (0)
Data not yet available